What type of carcinoma is Theraspheres (Nordion) approved for?

Therasphere, which contains microspheres that deliver locally radiative treatment, is specifically approved for hepatocellular carcinoma (HCC). This type of cancer originates in the liver and is the most common primary liver cancer. The effectiveness of Therasphere stems from its ability to administer targeted radiation directly to liver tumors, minimizing the damage to surrounding healthy tissue. This local approach is particularly beneficial for treating HCC, given the tumor's typical location and the challenges posed by traditional systemic treatments.

The other types of carcinoma listed do not have the same specificity for Therasphere's approval, as it is not used for localized treatment of breast, colon, or lung carcinomas in the same manner as it is for hepatocellular carcinoma. The focus on HCC reflects the unique capabilities of this therapy in managing liver cancer effectively.